FDA approves a new capsule form and a new tablet dosage for the Parkinson drug Nuplazid
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Acadia Pharmaceuticals announced that the United StatesThe FDA(approved a new capsule dosage form (34 mg) and a new tablet dose (10 mg) for Parkinson'sdrug(34 mg) to help patients treat psychotic symptoms such as Parkinson's disease (PD)-related hallucinations and delusions34mg Nuplazid capsules and 10mg tablets will be available in the U.Sin mid-August34mg Nuplazid capsulewill will provide the patient with the recommended daily dose of 34mg, reducing the patient's drug burden compared to the current recommended 2 17mg dose tabletsin addition, the FDA approved 10mg tablets of this size, which will provide an optimized low dose strength for patients who are receiving powerful cytochrome 3A4 inhibitors that inhibit Nuplazid metabolism at the same timein the U.S., Nuplazid was approved by the FDA in May 2016, becoming the first drug approved to treat psychotic symptoms such as hallucinations and delusions experienced in PD patientsNuplazid's approval marks a major milestone in the clinical treatment of Parkinson's diseasePreviously, the FDA qualified Nuplazid's breakthrough drug in 2014Nuplazid is also the FDA-approved first drug to selectively target 5-HT2A receptors, which play an important role in Parkinson's diseaseNuplazid's unique pharmacology pioneered a new drug category, Selective 5 Serotonin Reverse Agovizer (SSIA), which not only prioritizes 5-HT2A receptors, but also avoids dopamine receptor and other receptor activation side effects that most schizophrenia drugs haveConventional Parkinson's disease therapy contains drugs that stimulate dopamine to treat motor symptoms such as tremors, muscle stiffness and difficulty walkingNuplazid has a novel selective mechanism to treat hallucinations and delusions in a new way, and the drug does not have dopamine receptor activity and does not interfere with dopamine therapy in patients and therefore does not affect the motor function of Parkinson's patientsIn clinical studies, Nuplazid significantly reduced the frequency and severity of psychiatric symptoms compared to placebos without impairing motor function The industry is also very bullish on Nuplazid's business prospects, with Valuate Pharma expecting sales of $841 million by 2020 and analysis (the division expects Nuplazid to become a $1 billion-a-year drug in five years)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.